Chimerix, Inc. To Present A Summary Of Brincidofovir’s (CMX001) Hematologic Safety At The Annual Meeting Of The European Group For Blood And Marrow Transplantation

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DURHAM, N.C., March 24, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced an upcoming presentation on its investigational broad-spectrum antiviral brincidofovir (CMX001) at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) being held March 30 – April 2, 2014 in Milan, Italy.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC